KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Assets (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Current Assets for 6 consecutive years, with $695.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 6.43% year-over-year to $695.1 million, compared with a TTM value of $695.1 million through Sep 2025, down 79.66%, and an annual FY2024 reading of $751.4 million, down 13.83% over the prior year.
  • Current Assets was $695.1 million for Q3 2025 at AbCellera Biologics, down from $742.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.2 billion in Q1 2022 and bottomed at $695.1 million in Q3 2025.
  • Average Current Assets over 5 years is $886.3 million, with a median of $872.0 million recorded in 2023.
  • The sharpest move saw Current Assets skyrocketed 32.4% in 2022, then fell 19.9% in 2023.
  • Year by year, Current Assets stood at $929.8 million in 2021, then increased by 10.29% to $1.0 billion in 2022, then fell by 14.97% to $872.0 million in 2023, then decreased by 13.83% to $751.4 million in 2024, then dropped by 7.48% to $695.1 million in 2025.
  • Business Quant data shows Current Assets for ABCL at $695.1 million in Q3 2025, $742.1 million in Q2 2025, and $765.0 million in Q1 2025.